My Antidepressant Isn't Working — What Are My Options in New York?

You gave it time. You took it every day. You waited the six weeks, then the eight weeks, then the twelve — because everyone said to give it time. And things either didn't change, changed barely, or changed enough to take the edge off but not enough to feel like yourself again.

This is one of the most common experiences in psychiatry and one of the least talked about. The assumption when you start an antidepressant is that it will work. When it doesn't — or doesn't work well enough — it can feel like a personal failure, like your depression is somehow beyond fixing, or like the next step is just another version of the same disappointment.

None of that is true. Not responding adequately to a first or even second antidepressant is not a dead end. It is a clinical signal that points toward a more specific set of next steps — and in New York, those next steps are available.

Why Antidepressants Don't Always Work

Understanding why your antidepressant may not be working is the first step toward finding something that does.

You may not have been on it long enough at the right dose. This sounds frustrating to hear, but it is genuinely common. Antidepressants are frequently started at low doses, not titrated adequately, or discontinued before they've had a real chance to work. Six weeks at a starting dose is not always a fair trial. Before concluding a medication has failed, it's worth reviewing whether the trial was actually adequate.

Your depression may have a different neurobiological profile. Most standard antidepressants — SSRIs and SNRIs — work on serotonin and norepinephrine systems. But depression is not one disease. Some presentations involve glutamatergic dysfunction, inflammatory pathways, or HPA axis dysregulation that serotonergic medications don't adequately address. For these individuals, the problem isn't willpower or compliance — it's that the medication is targeting the wrong system.

There may be an undiagnosed co-occurring condition. Untreated anxiety, ADHD, trauma, bipolar spectrum disorder, sleep disorders, or substance use can all blunt antidepressant response. Treating depression without addressing co-occurring conditions is like bailing a boat without fixing the hole.

Pharmacogenomic factors may be limiting your response. Genetic variation affects how individuals metabolize psychiatric medications. Some people clear medications too quickly to achieve therapeutic levels. Others accumulate them at higher concentrations than expected. Pharmacogenomic testing can identify these patterns and help guide more targeted medication selection.

What "Not Working" Actually Means Clinically

Before exploring next steps, it helps to be precise about what you're experiencing — because "not working" can mean several different things that point toward different solutions.

Partial response — You feel somewhat better but significant symptoms remain. This is the most common scenario. Partial response often responds well to dose optimization, augmentation strategies, or adding therapy to the medication plan.

No response — Symptoms haven't changed meaningfully after an adequate trial. This suggests either the medication class isn't the right fit, the dose was insufficient, or there's an unaddressed factor limiting response.

Response that wore off — You felt better initially but the effect faded over months. This is sometimes called tachyphylaxis or "poop-out" and may respond to dose adjustment, switching agents, or adding augmentation.

Intolerable side effects — The medication may have been helping but the side effects — weight gain, sexual dysfunction, emotional blunting, sleep disruption — made it unsustainable. This is not failure; it's information that guides the next medication choice.

What the Next Steps Actually Look Like

Thorough reassessment before anything else

The most valuable thing you can do when an antidepressant hasn't worked is not immediately try the next one on the list. It's to step back and do a comprehensive reassessment — reviewing your full diagnostic picture, the adequacy of prior trials, co-occurring conditions, and factors that may be limiting your response. This is what separates good psychiatric care from the medication carousel.

Medication optimization

If the current medication has produced partial response, optimizing the dose before switching is often the right move. If switching is appropriate, moving to a different class of antidepressant — from SSRI to SNRI, or to bupropion, mirtazapine, or tricyclics — is a reasonable next step. Augmentation with lithium, atypical antipsychotics like aripiprazole or quetiapine, or thyroid supplementation can enhance response when a medication is partially effective.

Therapy alongside medication

Research consistently shows that combined treatment — medication plus evidence-based psychotherapy — produces better outcomes than medication alone for moderate to severe depression. If you've been on antidepressants without concurrent therapy, adding CBT or another evidence-based approach is a legitimate next step that doesn't require changing medications.

Spravato® (esketamine) for treatment-resistant depression

If you've tried at least two antidepressants at adequate doses and durations without sufficient improvement, you may meet criteria for treatment-resistant depression — and Spravato® becomes a clinically appropriate option to discuss.

Spravato® is FDA-approved specifically for this situation. It works through the glutamate system — a completely different neurobiological pathway from SSRIs and SNRIs — which is why it can work for people who haven't responded to multiple serotonergic medications. Some patients experience meaningful symptom relief within hours to days of their first session, compared to the weeks required by oral antidepressants.

It is not a take-home medication. Every session is administered in a certified clinical setting under direct supervision, with a two-hour monitoring period. It is used alongside an oral antidepressant as part of a broader treatment plan — not as a standalone replacement.

For New Yorkers who have been on the antidepressant treadmill without adequate results, Spravato® represents a meaningfully different option that is available locally — not just at specialized centers.

Questions to Ask Your Psychiatrist

If your antidepressant isn't working and you're not sure what to do next, here are the right questions to drive the conversation:

• Was my trial at an adequate dose and for an adequate duration?

• Is there a co-occurring condition that may be limiting my response?

• Have we reviewed my full diagnostic picture recently, or are we working from the original assessment?

• Am I a candidate for augmentation rather than switching?

• Should we consider pharmacogenomic testing?

• Do I meet criteria for treatment-resistant depression, and if so, what advanced options are available?

A psychiatrist who is doing their job well will welcome these questions. If they're dismissed, that tells you something important about whether you're in the right place.

Getting a Second Opinion in New York

If you've been in treatment for months or years without adequate improvement and your current provider hasn't raised any of the above options, a second opinion is completely appropriate. In psychiatry, as in all of medicine, a fresh set of eyes — particularly from a provider experienced in treatment-resistant presentations — can identify angles that prior providers missed.

At Aurora Wellness, our team of board-certified psychiatrists, NPs, and PA-Cs has deep experience managing depression that hasn't responded to initial treatment. We conduct thorough reassessments — not just a new prescription — and have access to the full range of next-step options including Spravato® treatment at our Brooklyn and White Plains locations. Therapy and psychiatric medication management are available via telehealth throughout New York State. If your antidepressant isn't working and you're not sure what comes next, a consultation with our team is the right place to start that conversation.